-
1 Comment
From a valuation standpoint, the stock is 97.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 39.6.
Based on the above factors, Ikena Oncology, Inc. Common Stock gets an overall score of 1/5.
| Exchange | NASDAQ |
|---|---|
| ISIN | US45175G1085 |
| Sector | Healthcare |
| Industry | Biotechnology |
| CurrencyCode | USD |
| Market Cap | 58M |
|---|---|
| PE Ratio | None |
| Beta | 0.48 |
| Target Price | 3 |
| Dividend Yield | None |
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for IKNA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
